Orelabrutinib plus Pola‑R‑CHP for untreated non‑GCB diffuse large B‑cell lymphoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 2 interventional trial gives treatment‑naive adults with non‑GCB DLBCL six 21‑day cycles of orelabrutinib combined with the Pola‑R‑CHP regimen and performs an interim efficacy and safety assessment after cycle six. Patients achieving a complete or partial response then receive two additional cycles of orelabrutinib with rituximab for a total of eight induction cycles, followed by a final evaluation. Eligible participants are 18–80 years old with measurable disease, ECOG 0–2 and adequate organ function, while those with CNS involvement or certain lymphoma subtypes are excluded. The combination of a BTK inhibitor with the Pola‑R‑CHP backbone is novel and the trial will provide initial safety and efficacy data for this approach.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age 18 to 80 years old.
2. Diffuse large B-cell lymphoma (DLBCL) confirmed by tumor tissue pathology, with at least one measurable lesion.
3. Non-GCB.
4. No prior anti-tumor treatment.
5. ECOG score of 0-2.
6. Life expectancy of ≥6 months.
7. Voluntary written informed consent.

Exclusion Criteria:

1. Lymphoma involving the central nervous system or leptomeningeal metastasis.
2. Transformed lymphoma, that is, transformed from other types of lymphoma, such as follicular lymphoma, marginal zone lymphoma, chronic lymphocytic leukemia, or small B-cell lymphoma.
3. Primary mediastinal large B-cell lymphoma.
4. Burkitt lymphoma.
5. Laboratory values at screening (unless due to lymphoma):

   1. Neutrophils \<1.5×10⁹/L;
   2. Platelets \<75×10⁹/L;
   3. ALT or AST more than 2 times the upper limit of normal, ALP and bilirubin more than 1.5 times the upper limit of normal;
   4. Creatinine level more than 1.5 times the upper limit of normal.
6. Patients with psychiatric disorders or other known or suspected inability to fully comply with the study protocol.
7. Pregnant or breastfeeding women.
8. Known human immunodeficiency virus (HIV) infection, or active hepatitis B or C virus infection (positive result by polymerase chain reaction \[PCR\]). If the patient tests positive for HbsAg, HBV DNA testing is required. If HBV DNA \<10³ IU/ml, the patient may be enrolled. If the patient tests negative for HbsAg but positive for HBcAb (regardless of HBsAb status), HBV DNA testing is also required. If HBV DNA \<10³ IU/ml, the patient may be enrolled. If the patient tests positive for HCV antibody, HCV RNA is detected by PCR. If positive, the patient meets the exclusion criteria.
9. Need for continuous treatment with strong or moderate CYP3A inhibitors or CYP3A inducers.
10. Inability to swallow capsules or significant gastrointestinal disorders, such as malabsorption syndrome, bariatric surgery, inflammatory bowel disease, or partial or complete intestinal obstruction.
11. Other concurrent and uncontrolled medical conditions that the investigator believes will affect the patient's participation in the study.

Where it's running

• Second Affiliated Hospital, School of Medicine, Zhejiang University
  Hangzhou, Zhejiang, China Recruiting

Study contacts

• Study coordinator: hui Liu
• Email: sylen@zju.edu.cn
• Phone: +86 13819198629

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Combining orelabrutinib with R-CHOP for treating CD5-positive DLBCL

  This study is testing if adding a new drug called orelabrutinib to the standard R-CHOP treatment can help people with untreated CD5-positive diffuse large B-cell lymphoma live longer without their cancer coming back.

  Recruiting at 11 sites Phase 2 Sun Yat-sen University · Guangzhou, China and 10 other locations · NCT06647940

• ctDNA testing in newly diagnosed DLBCL or HGBL to predict treatment outcomes

  This study checks if measuring circulating tumor DNA in blood after first-line therapy can predict whether the disease will stay away or come back in people with DLBCL or HGBL.

  Recruiting at 2 sites Peking University People's Hospital · Beijing, Beijing Municipality and 1 other locations · NCT07878351

• Proton Therapy for Mediastinal Lymphoma in Denmark

  This study tests whether using proton therapy for mediastinal lymphoma can lower late-toxicity risk compared with photon therapy in adults.

  Recruiting Copenhagen University Hospital, Rigshospitalet · Copenhagen, Select A State · NCT07817641

• Memory-Enhanced CAR-T Therapy for Relapsed/Refractory Large B-Cell Lymphoma

  This trial tests memory-enhanced 7×19-THEMIS CAR-T cells in adults with relapsed or refractory large B-cell lymphoma to see how safe they are and whether tumors shrink or disappear.

  Recruiting Phase 1/2 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT07788118

• Orelabrutinib plus Pola-R-CHP as first-line treatment for intermediate- to high-risk DLBCL

  This trial tests whether adding orelabrutinib to the Pola-R-CHP regimen can improve outcomes for adults with intermediate- to high-risk newly diagnosed DLBCL.

  Recruiting at 2 sites The First Affiliated Hospital of Xiamen University · Xiamen, Fujian and 1 other locations · NCT07778212

• UB-VV400 with rapamycin in relapsed/refractory B-cell lymphomas

  A phase 1/2 trial tests UB-VV400 plus rapamycin in adults with relapsed or refractory B-cell lymphomas to see if it is safe and shows anti-tumor activity.

  Recruiting at 2 sites Phase 1/2 Umoja Biopharma · Irvine, California and 1 other locations · NCT07735533

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.